These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19515449)

  • 1. A short cut to predict the clinical response to beta-blocker therapy in cirrhosis?
    Merkel C
    J Hepatol; 2009 Aug; 51(2):268-70. PubMed ID: 19515449
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients.
    Sharma P; Kumar A; Jha S; Mishra SR; Sharma BC; Sarin SK
    Aliment Pharmacol Ther; 2010 Jul; 32(1):105-12. PubMed ID: 20345511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes!
    Merkel C; Montagnese S
    Eur J Intern Med; 2011 Feb; 22(1):1-4. PubMed ID: 21238883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing the development of varices in cirrhosis.
    Garcia-Tsao G
    J Clin Gastroenterol; 2007; 41 Suppl 3():S300-4. PubMed ID: 17975480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as a guide for prophylaxis and therapy of bleeding and rebleeding? No.
    Thalheimer U; Bellis L; Puoti C; Burroughs AK
    Eur J Intern Med; 2011 Feb; 22(1):5-7. PubMed ID: 21238884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment arterial hypertension by beta-adrenergic blockers in elderly patients with gastrointestinal disorders].
    Komissarenko IA
    Eksp Klin Gastroenterol; 2002; (4):18-20, 130. PubMed ID: 12503267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers to prevent esophageal varices--an unfulfilled promise.
    Mukherjee S; Sorrell MF
    N Engl J Med; 2005 Nov; 353(21):2288-90. PubMed ID: 16306528
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacologic Treatment of Portal Hypertension.
    Wong YJ; Abraldes JG
    Clin Liver Dis; 2024 Aug; 28(3):417-435. PubMed ID: 38945635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival with nonselective beta blockers.
    Thalheimer U; Bosch J; Patch D; Burroughs A
    Hepatology; 2008 Dec; 48(6):2091-2. PubMed ID: 19030169
    [No Abstract]   [Full Text] [Related]  

  • 13. Betablocker, hepatic functions and confusion.
    Bhalla A
    J Assoc Physicians India; 1999 Feb; 47(2):254-5. PubMed ID: 10999112
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence.
    Thalheimer U; Christie J; Burroughs AK
    Am J Gastroenterol; 2012 Oct; 107(10):1593. PubMed ID: 23034623
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparative evaluation of the effectiveness of different schemes of correction the portal system pressure in patients with liver cirrhosis].
    Sirchak IeS
    Lik Sprava; 2013; (3):32-9. PubMed ID: 25016744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
    J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of portal hypertension.
    Miñano C; Garcia-Tsao G
    Gastroenterol Clin North Am; 2010 Sep; 39(3):681-95. PubMed ID: 20951924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers.
    Madsen BS; Havelund T; Krag A
    Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correction of portal hypertension by beta-adrenoblockers (atenolol and metoprolol) and inhibitors of ACE (lisinopril and enalapril) in liver cirrhosis].
    Lazebnik LB; Mikheeva OM; Toporkov AS; Komissarenko IA; Vasnev OS; Fedulenkova LV
    Eksp Klin Gastroenterol; 2007; (5):57-66. PubMed ID: 18389599
    [No Abstract]   [Full Text] [Related]  

  • 20. [Beta-adrenergic inhibitors and portal hypertension].
    Lebrec D
    Therapie; 1985; 40(6):403-6. PubMed ID: 2868535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.